WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1997037644) TREATMENT OF A HEMOGLOBINOPATHY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1997/037644    International Application No.:    PCT/US1997/005633
Publication Date: 16.10.1997 International Filing Date: 03.04.1997
Chapter 2 Demand Filed:    24.09.1997    
IPC:
A61K 31/131 (2006.01), A61K 31/155 (2006.01), A61K 31/198 (2006.01), A61K 31/21 (2006.01), A61K 31/295 (2006.01), A61K 33/00 (2006.01)
Applicants: THE GENERAL HOSPITAL CORPORATION [US/US]; 55 Fruit Street, Boston, MA 02110 (US) (For All Designated States Except US).
HEAD, C., Alvin [US/US]; (US) (For US Only).
ZAPOL, Warren, M. [US/US]; (US) (For US Only)
Inventors: HEAD, C., Alvin; (US).
ZAPOL, Warren, M.; (US)
Agent: FRASER, Janis, K.; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110 (US)
Priority Data:
60/014,886 05.04.1996 US
Title (EN) TREATMENT OF A HEMOGLOBINOPATHY
(FR) TRAITEMENT D'UN TYPE D'HEMOGLOBINOSE
Abstract: front page image
(EN)Disclosed are methods for treating a patient identified as having a hemoglobinopathy that is characterized by a reduced affinity of hemoglobin for oxygen. The methods involve providing gaseous nitric oxide and/or carbon monoxide for (i) inhalation by the patient or (ii) $i(ex vivo) treatment of the patient's erythrocytes. Alternatively, a nitric-oxide-releasing compound can be administered to the patient.
(FR)Cette invention concerne des procédés permettant de traiter un patient chez lequel on a décelé une hémoglobinose se caractérisant par une affinité réduite de l'hémoglobine envers l'oxygène. Ces procédés consistent à administrer au patient de l'oxyde d'azote et/ou du monoxyde de carbone gazeux (i) soit par inhalation, (ii) soit par un traitement $i(ex vivo) des érythrocytes du patient. Dans un autre mode de réalisation, on peut administrer au patient un composé libérant de l'oxyde d'azote.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN.
African Regional Intellectual Property Organization (GH, KE, LS, MW, SD, SZ, UG)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)